Mast cells are central in the development of several allergic diseases and contain a number of pre-formed mediators. -tryptase, the most abundant mast cell product, is increasingly recognized as a key inflammatory mediator as it causes the release of cytokines, particularly the chemokine IL-8, from both inflammatory and structural cells. The molecular mechanisms, however, remain largely unknown. In this study we sought to investigate whether -tryptase could induce IL-8 expression in human airway smooth muscle (ASM) cells and to explore the molecular mechanisms involved. We found that purified human -tryptase stimulated IL-8 production time-and concentration-dependently, which was inhibited by protease inhibitors 3
INTRODUCTION

Mast cells are widely recognized as critical effector cells in various allergic disorders and
other immunoglobulin E-associated acquired immune responses (1) . However, it is still unclear how they contribute to the respective conditions. One clear possibility is that one or more of the compounds present in the mast cell secretory granule, which are released after mast cell stimulation, contribute to a pathological response (2) . Tryptase (EC. 3.4.21.59 ) is the most abundant and a unique mast cell product (3) . Human tryptase is a serine protease and exists as 3 isoforms (the soluble and isoforms and the membrane anchored isoform) with -tryptase predominating in lung mast cells (2, 3) . -tryptase is stored in mast cell granules as enzymatically active tetramers in a complex with heparin, which facilitates the conversion of -tryptase monomers to tetramers and stabilizes them (4) . Because -tryptase is the main type of tryptase that is released during mast cell degranulation and isolated from normal human lung tissues, -tryptase produced recombinantly will be subsequently referred to as "tryptase".
Research on tryptase so far has revealed a large number of potential functions for this enzyme and identified it as a key inflammatory mediator in mast cell-related diseases and a potential target for therapeutic intervention (2) . Tryptase has been shown to stimulate the release of chemokine IL-8 from various inflammatory and structural cells such as eosinophils (5) , neutrophils (6) , endothelial cells (7, 8) , and epithelial cells (9) but the mechanisms involved are poorly defined. Since IL-8 is a potent chemoattractant for a number of granulocytes, particularly neutrophils and eosinophils, and to a lesser extent mast cells, tryptase may play a key role in neutrophilic and eosinophilic inflammatory diseases.
Work carried out by our group and others has shown that human ASM cells have important synthetic functions, which contribute to chronic airway inflammation and remodelling in airway diseases such as asthma (10) . Recent studies by Brightling and associates (11) have demonstrated a selective localisation of mast cells within the airway smooth muscle (ASM) layer in asthma, suggesting that mast cell products, including tryptase, may influence the synthetic functions of human ASM cells. Indeed, tryptase has been shown to stimulate human ASM cells to attract mast cells largely though the production of functionally active transforming growth factor 1 (TGF-1) (12) . We have also reported recently that tryptase selectively cleaves human ASM cell-derived eotaxin and regulated on activation, normal T cell expressed and secreted (RANTES) and abrogates their eosinophil chemotactic activities (13) .
It has been shown that tryptase exerts several of its cellular effects through cleavage of protease-activated receptor-2 (PAR-2). PAR-2 belongs to a family of four G-protein-coupled receptors [PAR- (1) (2) (3) (4) ]. The cleavage of the extracellular part of PAR-2, as for all of the PARs, leads to the exposure of a 'tethered' ligand which subsequently binds to the receptor, thereby inducing signalling events and receptor/ligand internalization (14) . Studies so far have demonstrated that tryptase-induced IL-8 production is mediated by PAR-2 in eosinophils and fibroblasts (5), neutrophils (6) , endothelial cells (8) and epithelial cells (9) . However, it is interesting to note that some effects of tryptase, notably ASM cell proliferation, are mediated via a PAR-2-independent nonproteolytic mechanism (15).
The mechanisms involved in IL-8 regulation have been studied with respect to cytokines in several cell types but less information is available for other agents and none for tryptase.
IL-8 can be regulated at both transcriptional and post-transcriptional levels. The nucleotide sequence -1 to -162 in the 5' flanking region of the IL-8 gene promoter contains binding sites for transcription factors activator protein-1 (AP-1), CCAAT/enhancer binding protein (C/EBP), and nuclear factor (NF)-κB. These are essential for IL-8 gene transcription in response to cytokines in some cells but not others (16, 17) . We have previously demonstrated that human ASM cells are a rich source of IL-8 (18) (19) (20) and that transcription factors AP-1, (21) . Although tryptase has been shown to induce IL-8 production in other cells through PAR-2 activation, the molecular mechanisms through which tryptase carries out its actions on IL-8 gene expression remains unclear.
In the present study we sought to determine whether tryptase could upregulate IL-8 expression in human ASM cells and to characterise the mechanisms involved. We found that IL-8 was released in large quantities from human ASM cells stimulated by tryptase and that the effect of tryptase was via a PAR-2-independent proteolytic mechanism. The regulation of IL-8 gene expression was partly transcriptional and partly post-transcriptional. Furthermore, transcriptional regulation was dependent on activation of transcription factors AP-1, C/EBP and NF-κB.
MATERIALS AND METHODS
Materials
Purified human lung tryptase dissolved in tryptase buffer (50mM NaOAc, 1M NaCl, 0.05mM heparin pH5.0 and 0.01% NaN 3 ) was obtained from Europa Bioproducts (Cambridge, UK, specific activity: 12,870 mU/mg protein using n-benzyl-DL-arginine-pNA as substrate); recombinant human lung tryptase (rh-tryptase) was from Promega (Southampton, UK specific activity: 1000 Units/mg protein using Nα CBZ-L-lysine thiobenzyl ester as substrate); 
Cell Culture
Human ASM were obtained from post-mortem tracheal specimens from four individuals with no history of respiratory diseases and no evidence of airway abnormalities as previously reported (22) . Cells were used at passage 6-7. When grown in this manner they depict the phenotypical characteristics of typical human ASM cells (22) .
Normal human bronchial/tracheal epithelial (NHBE) cells were obtained from Cambrex Bio Science Walkersville, Inc. (Walkersville, MD, USA) and were cultured using the company's own Bronchial Epithelial Cell Medium. Cells at passage 4 were used.
Cells were grown to confluence in 24 well plates and growth arrested for 24 hours prior to treatment. Purified tryptase, recombinant tryptase, SLIGKV-NH2, and bradykinin were diluted in serum-free medium. Vehicle controls were used in the inhibitor studies. The effect of drugs and drug vehicles on cell viability was assessed by thiazolyl blue, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltertrazolium bromide (MTT) assay as previously described (22) , no cytotoxic effect was observed (data not shown).
IL-8 Assay
The concentration of IL-8 in the supernatants was quantitated by ELISA as previously described (19, 20) .
RNA Isolation and RT-PCR
Confluent human ASM cells were serum-starved for 24 hrs. agarose gel and density analysis of the bands was conducted using GeneGenius gel documentation and analysis system (Syngene, Cambridge, UK).
Quantitative Real-Time PCR
IL-8 expression was determined using primer sequences described above. β 2 -microglobulin was used as the house keeping gene (23) . Quantitative PCR was performed on an ABI prism 7700 (Applied Biosystems) using Excite real-time Mastermix with SYBR green as described previously (23) .
IL-8 mRNA Stability
Confluent and serum-starved cells were treated with or without tryptase for 4 h before the addition of actinomycin D (5 µg/ml) for the times indicated to block new transcript generation. Total RNA were then extracted and RT-PCR was performed.
Western Blotting
Confluent and growth arrested human ASM cells and NHBE cells in 6-well plates were washed twice with ice-cold PBS and incubated for 2 min with a total cell lysis buffer (50 mM Tris-HCl, pH 7.4, 1% Triton X-100, 0.25% Na-deoxycholate, 150 mM NaCl, 1mM EDTA, 1 mM phenylmethylsulphonyl, and Sigma Protease inhibitor cocktail (1:100)) with gentle shaking. The samples were collected and centrifuged, and the protein concentration in the supernatant was determined using the Bio-Rad protein assay reagent.
PAR-2 protein expression was analyzed by Western blotting as described before (22) . 
DNA Constructs
The vectors encoding either the wild-type IL-8 promoter (-162/+44)/luciferase reporter, or site mutations of one of the binding sites (AP-1, C/EBP, or NF-B) in the IL-8 promoter region were kindly provided by Dr A. R. Braiser (Sealy Centre for Molecular Science, Galveston, TX, USA) and were described in detail in Dr Braiser's publications (24, 25) . The NF-Bdependent reporter 6 Btkluc, which contains six copies of the consensus NF-B binding site (5'-GGG ACT TTC C-3'), was a gift from Dr R Newton (Calgary, Canada) and has been previously described (26) . The AP-1 reporter construct pRTU14 was a gift from Dr A Kieser (Hanover, Germany) and consists of a luciferase gene under the control of a minimal promoter and four TREs (12-O-tetradecanoate-13-acetate responsive element), to which the AP-1 transcription factor binds (27) . The C/EBP reporter construct containing a promoter construct of four repeated consensus binding sites for C/EBP in tandem, upstream of a luciferase reporter gene ptK18-Luc, was obtained from Dr H Yang (Harvard University, MA, USA) and has previously been described (28) .
Reporter Gene Assay
Transient transfections were performed using FuGene 6 transfection reagent as described previously (19, 23, 29) with slight modification. Briefly, human ASM cells were seeded into 24-well plates, grown to 60% confluence, and growth arrested for 8 h in serum-and antibiotic-free medium before being co-transfected with the firefly luciferase and the internal control Renilla luciferase plasmids (0.4 firefly + 4 ng Renilla well)
for 16 h. Cells were then treated with tryptase (0-15 mU/ml) for the indicated times and lysed.
Luciferase activities were measured using the dual-luciferase reporter assay system and relative light units (RLU) recorded. Relative luciferase activity was calculated by normalizing firefly luciferase activity against Renilla luciferase activity.
Chromatin Immunoprecipitation (ChIP)
To detect the binding of transcription factors to the IL-8 promoter, ChIP was performed using GAAGCTTGTGTGCTCTGCTG-3', which were specifically designed for the IL-8 promoter and were described previously (19) . The PCR products were then visualized and analyzed with the GeneGenius gel documentation and analysis system (Syngene, Cambridge, UK).
Statistics
Data were expressed as the mean ± standard error. Data from ELISA and luciferase reporter assays were analyzed by analysis of variance (ANOVA) and an unpaired two-tailed Student's t-test using GraphPad Prism (version 4) to determine the significant differences between the 12 means. A value of P .05 was accepted as significant.
RESULTS
Tryptase Stimulates IL-8 Protein Production from Human ASM Cells
To examine the effect of tryptase on IL-8 production, human ASM cells were treated with or without purified human lung tryptase (15 mU/ml) for up to 24 h. As shown in Figure 1A , IL-8 was produced constitutively from tryptase buffer-treated control ASM cells, but tryptase timedependently enhanced IL-8 protein production from human ASM cells with significant increases observed 8 and 24 h after incubation. Tryptase also induced a concentrationdependent increase in IL-8 production above basal level, reaching significance at 3.25 mU/ml and peaking at 30 mU/ml ( Figure 1B ). To confirm that the effect of purified tryptase was truly due to the activity of tryptase, rather than any other contaminating proteases or heparin, we compared the effect of purified and recombinant human tryptase (rh-tryptase). In the absence of heparin, rh-tryptase caused very little IL-8 production; however, in the presence of heparin, rh-tryptase enhanced IL-8 production in a similar concentration-dependent manner to that of purified tryptase ( Figure 1C ). Heparin alone was without effect (data not shown). Since purified tryptase was in a solution containing heparin, the results therefore indicate that the induction of IL-8 by tryptase requires the presence of heparin and that the effect of purified tryptase on IL-8 production is indeed due to the activity of tryptase. Purified tryptase (tryptase) was then used throughout the study.
Tryptase Increases IL-8 mRNA Levels via both Transcriptional and Post-transcriptional Mechanisms
To explore whether the effect of tryptase on IL-8 production from ASM cells was due to its 
Tryptase Acts Proteolytically via a Non-PAR-2 Mechanism
To determine if the effect of tryptase on IL-8 production from ASM cells was due to its proteolytic properties we studied the effect of protease inhibitors. We found that leupeptin (2.5 µg/ml), an inhibitor of serine and cysteine proteases, and a broad spectrum protease inhibitor cocktail (containing aprotinin, bestatin, E-64, leupeptin and pepstatin A), caused significant (p<0.001) and near total inhibition of tryptase-induced IL-8 production ( Figure   5A ). The effect of tryptase on IL-8 production was also markedly inhibited by the selective tryptase inhibitor FUT-175 (FUT, Ki=0.095nM for tryptase (30)) ( Figure 5B ). In contrast, IL-8 production induced by bradykinin peptide inflammatory mediator, was not affected by these protease inhibitors ( Figure 5C ). The results strongly suggest that the effect of purified tryptase on IL-8 production is due to the proteolytic activities of tryptase.
As tryptase has been shown to act through the PAR-2 receptor in other cell types ( We found that tryptase time-and concentration-dependently increased IL-8 release from human ASM cells. We used purified tryptase from a commercial source for these studies. To ensure that the effects of tryptase on IL-8 were indeed due to tryptase we confirmed these effects using recombinant human tryptase (rh-tryptase). Since the specific activities of these two tryptase preparations were measured with different substrates, even though the same concentrations of the two tryptases in terms of specific activities were used in the experiment, different quantities of these two tryptases were actually applied. For instance, 7.5 mU/ml of tryptase was the equivalent of 583 ng/ml, whereas 7.5 mU/ml of rh-tryptase was the equivalent of 7.5 ng/ml, the difference was about 78 fold. There may be a number of main reasons for this difference: different substrates in measuring specific activities, lost activity in the purified preparation, and the contaminating proteins in the purified preparation. However, since the aim of this experiment was to confirm the effect of tryptase on IL-8 production with rh-tryptase, different quantities of the two tryptase should not affect the final conclusion, particularly when the quantities of rh-tryptase were smaller than those of purified tryptase.
Indeed, we found that rh-tryptase increased IL-8 production in a similar manner to that of the purified preparation although as would be expected required the presence of heparin which had no effect on its own. This is consistent with our recent finding that recombinant human tryptase mimicked the effect of purified tryptase on the cleavage of eotaxin and RANTES only in the presence of heparin (13) . This is also consistent with the findings that rh-tryptase induces IL-8 production from eosinophils (5) and neutrophils (6) . Purified tryptase did not require exogenous heparin to induce IL-8 production because heparin was present in the tryptase preparation.
As tryptase has proteolytic properties we performed experiments to determine if these were involved in its mechanism of action on IL-8 gene expression. We applied leupeptin, a protease inhibitor cocktail and the selective tryptase inhibitor FUT-175 to inhibit the proteolytic activity of tryptase and found that all inhibited tryptase-induced IL-8 production but not bradykinin-induced IL-8 production, strongly suggesting that the effect of tryptase is mediated through a proteolytic mechanism. FUT-175 is a serine protease inhibitor. Although it inhibits other serine proteases such as trypsin (Ki=15 nM) and thrombin (Ki=900 nM), it is most potent against tryptase (Ki=0.095 nM) (30) . The fact that tryptase-induced IL-8 production from human ASM cells was significantly inhibited by FUT-175 at 0.01 nM and 0.1 nM in the current study also strongly suggests the proteolytic effect is tryptase specific. It is well documented that some of the cellular effects of tryptase are mediated by cleaving PAR-2 through its proteolytic activity (2, 14) . PAR-2 has been shown to be expressed in human ASM cells (31) We found that tryptase induction of wild-type IL-8 promoter activity was markedly reduced with the mutation at the binding sites for AP-1, C/EBP, or NFthat all three transcription factors are involved in the optimal IL-8 transcription by tryptase.
Consistent with this, tryptase also stimulated the activity of reporter gene constructs with multiple repeat of the binding sequences for AP-1, C/EBP, and NFTo confirm that these transcription factors were binding to the IL-8 promoter in native chromatin environment we performed chromatin immunoprecipitation (ChIP) assay as described in our previous studies (19, 23, 37) , and we found that all three transcription factors bound to the IL- Density analysis for the PCR gels of the above experiment was normalised against DNA input control and data were expressed as fold increase over 0 h (untreated). Each point represents the mean ± SEM of three experiments. * P < 0.05, ** P < 0.01, and *** P < 0.001 compared with control cells (B). *** ***
